ROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment

Inflammatory bowel disease (IBD), an immune-mediated chronic gastrointestinal disease, is difficult to treat because its specific pathogenic mechanisms are currently unclear, and its recurrence rate is high. Probiotic therapies have been used to treat IBD; however, challenges, including poor digesti...

Descripció completa

Dades bibliogràfiques

Autors principals:	Guangze Sang, Sizhen Wang, Qiwei Tai, Yunchang Zhang, Xufang Wang, Baoling Yan, Weiwei Jiang, Zhendong Chen, Linhong Sun, Jiao Zhou, Xiaoxian Wu, Zi Ye, Feng Yang, Jun Luo, Beibei Guo
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2026-12-01
Col·lecció:	Drug Delivery
Matèries:	Inflammatory bowel disease ulcerative colitis probiotics catechin Escherichia coli Nissle 1917
Accés en línia:	https://www.tandfonline.com/doi/10.1080/10717544.2026.2630460
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!